OYSTER POINT PHARMACEUTICALS
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).
OYSTER POINT PHARMACEUTICALS
Industry:
Biopharma Clinical Trials Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.oysterpointrx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
235.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Flying L Partners
Flying L Partners investment in Series B - Oyster Point Pharmaceuticals
Vida Ventures
Vida Ventures investment in Series B - Oyster Point Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series B - Oyster Point Pharmaceuticals
Invus
Invus investment in Series B - Oyster Point Pharmaceuticals
Versant Ventures
Versant Ventures investment in Series B - Oyster Point Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Series A - Oyster Point Pharmaceuticals
Versant Ventures
Versant Ventures investment in Series A - Oyster Point Pharmaceuticals
Official Site Inspections
http://www.oysterpointrx.com Semrush global rank: 3.82 M Semrush visits lastest month: 3.47 K
- Host name: edge.redirect.pizza
- IP address: 89.106.200.1
- Location: Luxembourg
- Latitude: 49.7498
- Longitude: 6.1661
- Timezone: Europe/Luxembourg
More informations about "Oyster Point Pharmaceuticals"
Oyster Point Pharmaceuticals - Crunchbase
Oyster Point Pharmaceuticals may be growing as indicated by the expansion of its headquarters, which has tripled in size, suggesting an increase in operational capacity. This physical expansion is a strong indicator of growth, reflecting a …See details»
Oyster Point Pharma - LinkedIn
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.See details»
Oyster Point Pharma Information - RocketReach
Oyster Point Pharma is a Pharmaceutical Manufacturing, Drug Manufacturing & Research, and Biopharma company located in Princeton, New Jersey with $27.2 million in revenue and 164 …See details»
Oyster Point Pharma - businessabc.net
Nov 18, 2024 Oyster Point was founded in 2014 by two industry veterans with decades of experience in the biopharmaceutical space. Oyster Point has since grown to become a leader …See details»
Oyster Point Company Profile 2024: Valuation, …
Information on acquisition, funding, investors, and executives for Oyster Point. Use the PitchBook Platform to explore the full profile.See details»
Oyster Point Pharma Staff Directory & Email Format - ContactOut
Explore Oyster Point Pharma staff directory for direct access to contact details on 278 employees including email format, email address and phone numbers.See details»
Oyster Point Pharma - ZoomInfo
View Oyster Point Pharma (www.oysterpointrx.com) location in New Jersey, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
About OYSTER POINT PHARMA, INC. | DxMultiomics
OYSTER POINT PHARMA, INC. | on DxMultiomics. Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of …See details»
Working at Oyster Point Pharma - Zippia
Find out what it's like to work at Oyster Point Pharma. See what kind of people work at Oyster Point Pharma, career paths working at Oyster Point Pharma, company culture, salaries, …See details»
Barry Rosenfield - Oyster Point Pharma
You are now leaving OysterPointRx.com. Would you like to continue?See details»
Oyster Point Pharma Expands Executive Leadership Team
Sep 19, 2019 Oyster Point Pharma, Inc., today announced the appointment of Dan Lochner, MBA as its Chief Financial Officer and John Snisarenko, MBA as Chief Commercial Officer. …See details»
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the
Aug 17, 2022 Copies of these filings are available online at www.oysterpointrx.com. Any forward-looking statement made in this press release speaks only as of the date of this release.See details»
Oyster Point Pharma, a Leading Ophthalmology-Focused …
Nov 7, 2022 Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. …See details»
Oyster Point Pharma Announces TYRVAYA® To Be Covered By the …
Aug 17, 2022 Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical …See details»
Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 …
PRINCETON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical …See details»
Oyster Point Pharma Announces Expanded Patient Access to …
Jul 27, 2022 TYRVAYA Now Covered by Commercial Prescription Drug Plans Managed by the Nation’s Top Three Pharmacy Benefit Manager (PBM) Group Purchasing Organizations …See details»
Oyster Point Pharma Reports First Quarter 2022 Financial Results …
May 5, 2022 “We are very pleased with the performance of Oyster Point Pharma’s first full quarter since the launch of TYRVAYA®.” said Jeffrey Nau, Ph.D., MMS, president and chief …See details»
Recommended Stories - Yahoo Finance
PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, …See details»
Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now …
Feb 22, 2022 One of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic …See details»